NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘Omega Funds’

22 January 2014

Venture capital-backed Dicerna prices IPO at $11 to $13 per share

dna Venture capital-backed RNA interference-based therapeutics developer Dicerna Pharmaceuticals has priced its IPO at $11 to $13 per share.

1 August 2013

RA Capital backs mammoth $60m Series C round for RNA Interference

dna RA Capital has helped emerging pharmaceutical company RNA Interference close an enormous $60m Series C financing round.

23 July 2013

German medical device company JenaValve Technology inks $62.5m investment

German medical device company JenaValve Technology has raised $62.5m in a Series C venture round led by Belgium-based investment firm Gimv, alongside new investors including Beijing-based Legend Capital and healthcare-focused Omega Funds.

9 November 2012

Gates Foundation, Omega help Visterra close $26m Series A

Visterra, a developer of medicines to prevent and treat infectious diseases, has raised an additional $13m to complete a $26m Series A financing.


Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014